Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced that the first order of rintatolimod (Ampligen®) for the Early Access Program (EAP) in Europe has been shipped with receipt confirmed on July 22. On May 23, 2016, the Company executed an amended and restated agreement with Impatients N.V., a Netherlands-based company operating as myTomorrows, for the commencement and management of an Early Access Program (EAP) in all of Europe and Turkey. Ampligen® is the trade name in the United States for rintatolimod.
“This program will enable Chronic Fatigue Syndrome (CFS) patients, who face an unmet medical need in the EU, to access rintatolimod under early access regulations,” said Tom Equels, CEO of Hemispherx. “It will operate concurrently while we work with the FDA to determine a path toward approval in the United States. The initiation and implementation of our EAP out-reach is an important tangible step in our effort to make our experimental drug Ampligen® a commercially approved drug available to all those suffering from CFS.” (Original Source)
Shares of Hemispherx Biopharma closed last Friday at $0.1223, down $0.00 or -2.70%. HEB has a 1-year high of $0.20 and a 1-year low of $0.06. The stock’s 50-day moving average is $0.12 and its 200-day moving average is $0.12.
Hemispherx Biopharma, Inc. is a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and the experimental immunotherapeutic/antiviral Ampligen. Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Ampligen includes application as a treatment for Chronic Fatigue Syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments.